Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells $41,444.52 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $6.29 on Friday. Enanta Pharmaceuticals, Inc. has a one year low of $6.25 and a one year high of $17.80. The firm has a market cap of $133.31 million, a price-to-earnings ratio of -1.15 and a beta of 0.49. The firm has a 50 day simple moving average of $10.33 and a 200-day simple moving average of $11.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same period in the prior year, the firm posted ($1.33) earnings per share. The business’s quarterly revenue was down 22.8% compared to the same quarter last year. Equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ENTA. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth about $35,000. US Bancorp DE raised its position in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Enanta Pharmaceuticals during the third quarter worth approximately $122,000. Quest Partners LLC boosted its holdings in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares in the last quarter. Finally, Valence8 US LP purchased a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ENTA shares. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.